ÄãºÃ£¬»¶Ó­À´µ½¾­¹ÜÖ®¼Ò [µÇ¼] [×¢²á]

ÉèΪÊ×Ò³ | ¾­¹ÜÖ®¼ÒÊ×Ò³ | Êղر¾Õ¾

×éµ°°×È¥ÒÒõ£»¯Ã¸(HDACs)µÄÑо¿½øÕ¹_ҩѧרҵ±ÏÒµÂÛÎÄ·¶ÎÄ

·¢²¼Ê±¼ä£º2014-12-09 À´Ô´£ºÈË´ó¾­¼ÃÂÛ̳
×éµ°°×È¥ÒÒõ£»¯Ã¸(HDACs)µÄÑо¿½øÕ¹_ҩѧרҵ±ÏÒµÂÛÎÄ·¶ÎÄ ¡¾ÕªÒª¡¿  ÔÚÖ×ÁöµÄ±í¹ÛÒÅ´«Ñ§Ñо¿ÖУ¬×éµ°°×µÄÒÒõ£»¯ÐÞÊζÔÖ×ÁöµÄ·¢Éú·¢Õ¹ÆðÖØÒª×÷Óá£Õý³£Ï¸°ûÌåÒ»µ©³öÏÖºËÄÚ×éµ°°×ÒÒõ£»¯ÓëÈ¥ÒÒõ£»¯µÄʧºâ£¬¼´»áµ¼ÖÂÕý³£µÄϸ°ûÖÜÆÚÓëϸ°û´úлÐÐΪµÄ¸Ä±ä¶øÓÕ·¢Ö×Áö¡£×éµ°°×È¥ÒÒõ£»¯Ã¸(histone deacetylases£¬HDACs)´ß»¯×éµ°°×µÄÈ¥ÒÒõ£»¯£¬Î¬Ïµ×éµ°°×ÒÒõ£»¯ÓëÈ¥ÒÒõ£»¯µÄƽºâ״̬£¬Óë°©Ïà¹Ø»ùÒòת¼±í´ï¡¢Ï¸°ûÔöÖ³·Ö»¯¼°Ï¸°ûµòÍöµÈÖî¶à¹ý³ÌÃÜÇÐÏà¹Ø¡£±¾ÎÄ´Ó×éµ°°×È¥ÒÒõ£»¯Ã¸HDACsµÄ½á¹¹·ÖÀ༰ÆäÓëÖ×Áö·¢Éú·¢Õ¹¹ØϵÁ½·½Ãæ¶ÔHDACs×öÒ»×ÛÊö¡£ ¡¾¹Ø¼ü´Ê¡¿  ×éµ°°×È¥ÒÒõ£»¯Ã¸(HDACs);Ö×Áö;±í¹ÛÒÅ´«Ñ§ Abstract:The modification for histone acetylation is of great importance for formulation and development of tumors in the epigenetic study of tumors. The disequilibrium of histone acetylation and deacetylation may cause some changes of cell cycle and cell metabolism. Histone deacetylases (HDACs) catalyze the deacetylation of histones£¬and maintain the equilibrium between histone acetylation and deacetylation as well. They are related to many regulation processes containing transcription of oncogene£¬cell cycle£¬apoptosis and so on. The structure classification of HDACs and the relationship between the HDACs and the formation and advancement of tumor were reviewed in this paper. Key words:¡¡histone feacetylases (HDACs); tumor; epigenetics Ö×ÁöµÄ·¢ÉúÊÇÒ»¸ö¸´ÔӵIJ¡Àí¹ý³Ì£¬ÊܶàÖØÒòËصÄÓ°Ï죬°üÀ¨¸öÌåÒÅ´«ÒòËØ¡¢»·¾³ÒòËØ¡¢ÎïÀí»¯Ñ§ÒòËØ¡¢·Ö×ÓÉúÎïѧÒòËصȵȡ£Ëæ×ÅÉúÃü¿ÆѧµÄѸËÙ·¢Õ¹ºÍÓйØÖ×ÁöÖ²¡»úÖƺͷ¢²¡»úÖƵķÖ×ÓÉúÎïѧÑо¿µÄÉîÈ뿪չ£¬·Ö×ÓÉúÎïѧÒòËØÔÚÖ×Áö·¢ÉúÖеÄÍ»³ö×÷Óñ»Öð²½½Òʾ£¬Ó°Ïìϸ°ûÉú³¤¡¢ÔöÖ³µÄ»ùÒòºÍ²ÎÓëϸ°ûÉú³¤ÔöÖ³µ÷¿ØµÄ¸÷ÖÖÒò×ÓµÄʧ»î³ÉΪÖ×Áö·¢ÉúµÄ¹Ø¼üÓÕÒò¡£Ëæ×ÅÉúÃü¿ÆѧµÄÉîÈë·¢Õ¹£¬¶ÔÖ×ÁöµÄÖ²¡ºÍ·¢²¡»úÖƵķÖ×ÓÉúÎïѧÑо¿Îª¿ª·¢µÍ¶¾¸ßЧÕë¶ÔÌØÒìÐÔ·Ö×ӰбêµÄ¿¹Ö×ÁöÒ©ÎïÌṩÁË»ù´¡[1]¡£×éµ°°×È¥ÒÒõ£»¯Ã¸(histone deacetylases£¬HDACs)ÊÇά³ÖȾɫÌåµÄ»ù±¾×é³Éµ¥Î»ºËСÌåÖÐ×éµ°°×ÒÒõ£»¯Æ½ºâµÄ¹Ø¼üøÀàÖ®Ò»£¬Æä´ß»¯×éµ°°×µÄÈ¥ÒÒõ£»¯×÷Óã¬Óë»ùÒòת¼ÒÖÖÆÃÜÇÐÏà¹Ø£¬Ç£Éæµ½´Ù»ùÒò³ÁĬµÄÖî¶à¹ý³Ì£¬ÊÇ¿¹Ö×ÁöÒ©ÎïÉè¼ÆÖеÄÈÈÃŰбê[2]¡£±¾ÎľÍHDACsµÄ±í¹ÛÒÅ´«Ñ§×÷ÓᢷÖÀ༰½á¹¹¡¢ÓëÖ×Áö·¢Éú·¢Õ¹µÄ¹Øϵ×÷Ò»×ÛÊö£¬ÒÔÆÚΪºóÐø¿¹Ö×ÁöÑо¿ÌṩеÄ˼·¡£ 1HDACsµÄ±í¹ÛÒÅ´«Ñ§×÷Óà ±í¹ÛÒÅ´«Ñ§(epigenetics)ÊDz»Éæ¼°DNAÐòÁиıäµÄ¿ÉÒÅ´«µÄ»ùÒò±í´ï±ä»¯Ñо¿[3]£¬ÔÚÆäÖî¶àÐÎʽÖУ¬×éµ°°×µÄ¹²¼ÛÐÞÊÎÕ¼ÓÐÖØÒªµØ룬ÆäÓë»ùÒòµÄ±í´ïµ÷¿ØÃÜÇйØÁª£¬°üÀ¨Á×Ëữ¡¢ÒÒõ£»¯¡¢¼×»ù»¯ÐÞÊεȡ£×éµ°°×ÒÒõ£»¯¼°È¥ÒÒõ£»¯ÐÞÊÎÊÇ×îÖØÒªµÄ·½Ê½£¬ÊÇ»ùÒò±í´ïµ÷¿Ø×îÖ÷ÒªµÄÇý¶¯Á¦[4]£¬´Ë¿ÉÄæµÄ¶¯Ì¬ÐÞÊÎÓÉ×éµ°°×ÒÒõ£»ùתÒÆø(HAT)ºÍHDACs¹²Í¬´ß»¯£¬¹²Í¬¿ØÖÆȾɫÖʸ÷ÇøÓòºËÐÄ×éµ°°×µÄÒÒõ£»¯³Ì¶È¡£×éµ°°×µÄÒÒõ£»¯³Ì¶ÈÓëת¼»îÐÔÃÜÇÐÏà¹Ø£º×ªÂ¼»î¶¯ÇøÓòºËÐÄ×éµ°°×µÄÒÒõ£»¯Ãܶȸߣ¬¶ø²»»î¶¯ÇøÓòÒÒõ£»¯ÃܶȵÍ[5]¡£HAT´ÙʹȾɫÌåµÄ½â¾Û£¬¼¤»îת¼;¶øHDACsÔò·â±ÕDNA£¬½ø¶øÒÖÖÆת¼¹ý³Ì¡£ÔÚÕý³£ÉúÀí״̬Ï£¬HATÓëHDACs¶Ô×éµ°°×ÒÒõ£»¯×÷Óõĵ÷¿Ø´¦ÓÚƽºâ״̬¡£¶øϸ°ûÔÚ·¢Éúת»¯µÄ״̬Ï£¬HDACsµÄ»îÐÔÃ÷ÏÔÔöÇ¿£¬Ê¹µÃÔ­ÓеĻùÒò±í´ïƽºâ״̬±»´òÆÆ£¬µ¼ÖÂһЩӰÏìϸ°ûÔöÖ³ºÍµ÷¿Øϸ°ûÖÜÆڵķÖ×Ó±í´ïʧºâ£¬½ø¶øµ¼ÖÂϸ°û¶ñ±ä[6]¡£HDACs³ÉΪ±í¹ÛÒÅ´«Ñ§Öп¹Ö×ÁöÒ©ÎïÉè¼ÆµÄÖØÒªºÍDZÁ¦°Ðµã¡£ 2 HDACs·ÖÀ༰½á¹¹Ìصã 2.1·ÖÀà »ùÓÚ½ÍĸÖÖϵ·¢ÓýÖеIJ»Í¬HDACsµÄ½á¹¹Í¬Ô´ÐÔ·ÖÎö[7]£¬ÕæºËÉúÎïHDACs±»·Ö³É4Àࣺ¢ñÀàHDACsÓë½ÍĸRpd3¾ßÓÐͬԴÐÔ£¬°üÀ¨HDAC1¡¢HDAC2¡¢HDAC3¡¢HDAC8;¢òÀàHDACsÓë½ÍĸHda1¾ßÓÐͬԴÐÔ£¬°üÀ¨HDAC4¡¢HDAC5¡¢HDAC6¡¢HDAC7¡¢HDAC9ºÍHDAC10£¬Æä¸ù¾Ý´ß»¯ÇøÓòµÄ²»Í¬ÓÖ¿É·ÖΪ2Àࣺ¢òaÀà¾ßÓÐÒ»¶Î´ß»¯ÇøÓò£¬°üÀ¨HDAC4¡¢HDAC5¡¢HDAC7ºÍHDAC9£¬¢òbÀà¾ßÓÐÁ½¶Î´ß»¯ÇøÓò£¬Ö÷Òª°üÀ¨HDAC6ºÍHDAC10;¢óÀàHDACs¼´³ÁĬÐÅÏ¢µ÷½ÚÒò×Ó2(silent information regulator2£¬Sir2)-Ïà¹ØøÀà[8] (Sir2-related enzymes£¬sirtuins)£¬ÆäÊÇÑÌõ£°·ÏÙàÑßʶþºËÜÕËá(nicotinamide adenine dinucleotide£¬NAD+)ÒÀÀµµÄ×éµ°°×È¥ÒÒõ£»¯Ã¸Àà;¢ôÀàHDACsÖ÷ÒªÊÇHDAC11£¬ÆäÓë¢ñ¡¢¢òÀàHDACs²îÒì½Ï´ó¶ø±»¶ÀÁ¢»®¹éÒ»Àà¡£HDACs¼Ò×å¸÷³ÉÔ±Ö÷Òª¶¨Î»ÓÚϸ°ûºËÓëϸ°ûÖÊÖУ¬ÁíÓÐÉÙ²¿·Ö¶¨Î»ÓÚ°ûÖÊϸ°ûÆ÷ÈçÏßÁ£ÌåÖÐ(Ö÷ÒªÊÇ¢óÀàHDACsÖеÄSIRT3¡¢SIRT4ÓëSIRT5)£¬HDACs·¢»Ó´ß»¯×÷ÓõÄÄ¿±êµ°°×ÖÖÀà·±¶à£¬³£¼ûÈçÒÖ°©µ°°×p53¡¢ÈÈÐݿ˵°°×HSP70¡¢Smadsµ°°×¼Ò×åµÈ£¬HDACsÕýÊÇͨ¹ýÓë´ß»¯¶àÖÖÉúÀí¹ý³ÌÖеĹؼüµ°°×¶øÔÚµ÷¿ØÖ×Áö½ø³ÌÖз¢»ÓÖØÒª×÷Óᣠ2.2½á¹¹Ìصã 
¾­¹ÜÖ®¼Ò¡°Ñ§µÀ»á¡±Ð¡³ÌÐò
  • ɨÂë¼ÓÈë¡°¿¼ÑÐѧϰ±Ê¼ÇȺ¡±
ÍƼöÔĶÁ
¾­¼ÃѧÏà¹ØÎÄÕÂ
±êÇ©ÔÆ
¾­¹ÜÖ®¼Ò¾«²ÊÎÄÕÂÍƼö